Details for Patent: 12,673,047
✉ Email this page to a colleague
Which drugs does patent 12,673,047 protect, and when does it expire?
Patent 12,673,047 protects WIDAPLIK and is included in one NDA.
This patent has seventy-two patent family members in twenty-two countries.
Drugs Protected by US Patent 12,673,047
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | WIDAPLIK | amlodipine besylate; indapamide; telmisartan | TABLET;ORAL | 219423-003 | Jun 5, 2025 | DISCN | Yes | No | 12,673,047 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,673,047
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018213147 | ⤷ Start Trial | |||
| Australia | 2019309329 | ⤷ Start Trial | |||
| Australia | 2023274064 | ⤷ Start Trial | |||
| Australia | 2025201831 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
